Journal: Journal of Cosmetic Dermatology

Article Title: Revealing the Patient Perspective: Evolution of Patient‐Reported Outcome Measures in Botulinum Toxin Studies in Aesthetic Medicine

doi: 10.1111/jocd.70311

Figure Lengend Snippet: Timeline of key developments: PROs and onabotulinumtoxinA in facial aesthetic indications. a The clinical program underlying these approvals incorporated patients treated in all three upper facial areas (GL, LCL and FHL). CDE, Center for Drug Evaluation; EMA, European Medicines Agency; FDA, Food and Drug Administration; FHL, forehead lines; FLO‐11, Facial Line Outcomes Questionnaire; FLSQ, Facial Line Satisfaction Questionnaire; GL, glabellar lines; HRQoL, health‐related quality of life; ISPOR, Professional Society for Health Economics and Outcomes Research; LCL, lateral canthal lines; PFDD, patient‐focused drug development; PRO, patient‐reported outcome; UFL, upper facial lines.

Article Snippet: OnabotulinumtoxinA (BOTOX/BOTOX Cosmetic/Vistabel/Vistabex/BOTOX Vista, Allergan Aesthetics, an AbbVie Company, Irvine, CA) was the first BoNTA licensed in this setting and remains the most widely injected and broadly studied product available for treating the upper face—in particular, glabellar (GL), lateral canthal (LCL), and forehead lines (FHL).

Techniques:

Journal: Journal of Cosmetic Dermatology

Article Title: Why Dosing Matters: A Closer Look at the Dose–Response Relationship With OnabotulinumtoxinA

doi: 10.1111/jocd.70170

Figure Lengend Snippet: Key onabotulinumtoxinA dose‐ranging studies in UFL indications.

Article Snippet: Injectable botulinum neurotoxin formulations (BoNTs) are commonly used in aesthetic medicine [ , ], and onabotulinumtoxinA (Botox Cosmetic/Vistabel, Allergan Aesthetics, an AbbVie Company, Madison, NJ) is the most widely studied in this setting.

Techniques:

Journal: Journal of Cosmetic Dermatology

Article Title: Why Dosing Matters: A Closer Look at the Dose–Response Relationship With OnabotulinumtoxinA

doi: 10.1111/jocd.70170

Figure Lengend Snippet: Mean change from baseline in investigator‐assessed LCL severity at maximum smile in a dose‐ranging study of onabotulinumtoxinA. Study subjects were randomized to bilateral treatment on Day 0 with one of four onabotulinumtoxinA doses or placebo . LCL severity was assessed for each side separately on a four‐point scale. p < 0.05 for onabotulinumtoxinA versus placebo from Day 7 to Day 120 for the 6 U, 12 U, and 18 U doses, and from Day 7 until Day 30 for the 3 U dose. LCL, lateral canthal lines.

Article Snippet: Injectable botulinum neurotoxin formulations (BoNTs) are commonly used in aesthetic medicine [ , ], and onabotulinumtoxinA (Botox Cosmetic/Vistabel, Allergan Aesthetics, an AbbVie Company, Madison, NJ) is the most widely studied in this setting.

Techniques:

Journal: Journal of Cosmetic Dermatology

Article Title: Why Dosing Matters: A Closer Look at the Dose–Response Relationship With OnabotulinumtoxinA

doi: 10.1111/jocd.70170

Figure Lengend Snippet: Improvement in FHL following onabotulinumtoxinA treatment as assessed on FWS by investigators and study subjects. Patients were randomized to treatment with 10 or 20 U of onabotulinumtoxinA in the forehead, each combined with 20 U in the glabella (thus 30 or 40 U in total), or with placebo . Assessments were made at maximum eyebrow elevation. a p ≤ 0.05 through Day 120 (active arms vs. placebo). b N values were 59, 57 and 59 in the 30 U, 40 U, and placebo groups, respectively. c p ≤ 0.001 through Day 120 (active arms vs. placebo). FHL, forehead lines; FWS, Facial Wrinkle Scale; GL, glabellar lines.

Article Snippet: Injectable botulinum neurotoxin formulations (BoNTs) are commonly used in aesthetic medicine [ , ], and onabotulinumtoxinA (Botox Cosmetic/Vistabel, Allergan Aesthetics, an AbbVie Company, Madison, NJ) is the most widely studied in this setting.

Techniques:

Journal: Journal of Cosmetic Dermatology

Article Title: Why Dosing Matters: A Closer Look at the Dose–Response Relationship With OnabotulinumtoxinA

doi: 10.1111/jocd.70170

Figure Lengend Snippet: OnabotulinumtoxinA duration and dosing science: summary.

Article Snippet: Injectable botulinum neurotoxin formulations (BoNTs) are commonly used in aesthetic medicine [ , ], and onabotulinumtoxinA (Botox Cosmetic/Vistabel, Allergan Aesthetics, an AbbVie Company, Madison, NJ) is the most widely studied in this setting.

Techniques: Glycoproteomics, Derivative Assay

Journal: Medicine

Article Title: Psychological profile in women undergoing minimally invasive cosmetic procedures: A pilot–survey-based–retrospective study

doi: 10.1097/MD.0000000000042255

Figure Lengend Snippet: Histograms depicting number of BoNT, filler and total procedures in 37 MICPs participants in the last 2 years. BoNT = botulinum toxin, MICPs = minimally invasive cosmetic procedures.

Article Snippet: This was a descriptive cross-sectional study on 37 females (MICPS group) older than 18 years (mean age: 45.35 ± 10.49 years) who referred a cosmetic clinic for at least one procedure of BoNT (onabotulinumtoxinA; Botox Cosmetic/ONA; Allergan, Dublin, Ireland)and/or soft tissue filler (Stylage; Laboratoires Vivacy, Paris, France) injection during a 2-year (2021–2022) period.

Techniques: